Legend Biotech (LEGN) Set to Announce Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN - Get Free Report) will be announcing its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.49. Legend Biotech had a negative return on equity of 23.20% and a negative net margin of 62.50%. The firm had revenue of $186.50 million during the quarter, compared to analysts' expectations of $125.25 million. During the same quarter in the prior year, the company earned ($0.27) EPS. The company's revenue was up 154.4% on a year-over-year basis. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Up 2.3 %

Legend Biotech stock traded up $1.01 during midday trading on Tuesday, reaching $44.62. The stock had a trading volume of 2,992,200 shares, compared to its average volume of 1,067,809. The stock has a market capitalization of $8.13 billion, a P/E ratio of -57.20 and a beta of 0.11. The firm's fifty day simple moving average is $48.52 and its 200-day simple moving average is $48.59. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84. Legend Biotech has a 1-year low of $38.60 and a 1-year high of $70.13.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Scotiabank lifted their price target on shares of Legend Biotech from $70.00 to $76.00 and gave the company a "sector outperform" rating in a research note on Monday, August 12th. Royal Bank of Canada restated an "outperform" rating and issued a $86.00 price target on shares of Legend Biotech in a research note on Tuesday, October 29th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 price target on shares of Legend Biotech in a research report on Wednesday, October 16th. TD Cowen decreased their price objective on shares of Legend Biotech from $71.00 to $67.00 and set a "buy" rating for the company in a research report on Monday, July 15th. Finally, Redburn Atlantic began coverage on Legend Biotech in a report on Tuesday, October 8th. They set a "buy" rating and a $86.00 price target for the company. Fourteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $82.08.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).